Keyword: Regeneron Pharmaceuticals
Blockbusters Humira and Keytruda will lead 2024 sales, according to an EvaluatePharma report, joined by new Sanofi launch Dupixent.
Regeneron needs some Type A newcomers to backstop its aging blockbuster Eylea, but so far, its trio of launches are still seeking traction.
Regeneron and Sanofi have an exclusive PCSK9 deal with Express Scripts, but one analyst believes it's a negative for the companies.
Regeneron's George Yancopoulos won a bonus of sorts in 2012, and now he's vested. This year, though, he and CEO Len Schliefer took a small cut.
Amgen faces generic competition to its thyroid medication, Sensipar, and the potential to lose share in the PCSK9 cholesterol drug market. Now what?
Sanofi and Regeneron presented Odyssey outcomes data for Praluent at ACC 2018 Saturday.
Regeneron says a recent spike in a rare side effect for some Eylea patients is tied to some Becton Dickinson syringes that were distributed in the U.S.
Regeneron's Eylea has been a hit on the market for years. But now, the number of patients experiencing a rare side effect is climbing.
Psoriasis treatments are getting more effective. But that doesn’t mean patients have easy access to a new-and-improved crop of blockbuster hopefuls.
Monday, Axovant said COO Marion McCourt would be exit “to pursue another opportunity.” Turns out, that opportunity's at Regeneron.